The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France-Reference-Cited by-同舟云学术

The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France

Published:2006-10 Issue:10 Volume:28 Page:1686-1694
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Cramer Joyce A.,Lynch Niall O.,Gaudin Anne-Francoise,Walker Mel,Cowell Warren

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference45 articles.

1. Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis;Tsugeno;Osteoporos Int,2002

2. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis;World Health Organization,1994

3. Diagnosis of osteoporosis and assessment of fracture risk;Kanis;Lancet,2002

4. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Fou ndation;Ray;J Bone Miner Res,1997

5. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation;National Osteoporosis Foundation,2002

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilization outcomes of direct oral anticoagulants in Medicare patients;Research in Social and Administrative Pharmacy;2023-11

2. Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis;Osteoporosis and Sarcopenia;2022-09

3. Analysis of factors contributing to medication errors during self-management of medication in the rehabilitation ward: a case control study;BMC Health Services Research;2022-03-03

4. Predicting the individualized risk of nonadherence to zoledronic acid among osteoporosis patients receiving the first infusion of zoledronic acid: development and validation of new predictive nomograms;Therapeutic Advances in Chronic Disease;2022-01

5. Response to Letter to the Editor From Malozowski: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”;The Journal of Clinical Endocrinology & Metabolism;2021-12-16